Goldman Sachs Initiates Coverage On Royalty Pharma with Buy Rating, Announces Price Target of $42
Benzinga Newsdesk 1 year ago
NewsPrice TargetInitiationAnalyst Ratings
Goldman Sachs analyst Asad Haider initiates coverage on Royalty Pharma (NASDAQ:RPRX) with a Buy rating and announces Price Target of $42.
Goldman Sachs analyst Asad Haider initiates coverage on Royalty Pharma (NASDAQ:RPRX) with a Buy rating and announces Price Target of $42.